title: [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
authors.forename: Yuan-kai
authors.initials: YK
authors.lastname: Shi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000077547:Crizotinib; D043844:Crown Ethers / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D009154:Mutation; D057285:Precision Medicine; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011786:Quality Control; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D043844:Crown Ethers; D016756:Immunoglobulins, Intravenous; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D011799:Quinazolines; D000077547:Crizotinib; C531470:icotinib; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib; C525021:figitumumab